G&M Health, LLC’s Post

🌟 Important Update 🌟 Yesterday, the U.S. Senate passed a critical provision of the bipartisan Affordable Prescriptions for Patients Act, a victory for increased competition and lower pharmaceutical prices. Authored by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT), this legislation targets "patent thickets" that hinder competition and inflate costs. The Public Sector HealthCare Roundtable has long championed these reforms and applauds the bipartisan effort to pass this key provision. This is a significant step toward ending anti-competitive practices and passing drug savings along to public sector purchasers. Visit our website to learn more https://lnkd.in/ed_Nsr9T #Healthcare #AffordablePrescriptions #BipartisanSupport #PublicSector

We’re thrilled to share our latest article on the groundbreaking potential of Prescription Drug Use-Related Software (PDURS). Discover how PDURS is revolutionizing the way healthcare providers prescribe software alongside medications, enhancing patient care and management. Dive into the article to learn about: • The regulatory and clinical requirements for PDURS • The commercial impact and opportunities for pharmaceutical companies • Strategies for integrating digital solutions into patient care Don’t miss out on this innovative approach that’s shaping the future of digital medicine. Read more here: https://ow.ly/k88v50QUxjj. #DigitalHealth #PDURS

📰 Members of the Senate Oversight Committee put patients over pharmaceutical profits by reporting out Senate Bill (SB) 1179 to the full Senate, which adds state-level protections to the #340B program and the affordable, community-based care it supports ➡️ https://bit.ly/3BxqrsA #MiLeg #Protect340B

When it comes to rising #prescription drug costs, many have pointed the finger at prescription #drug middlemen known as pharmacy benefit managers (PBMs). But #advocates of PBMs, such as the Pharmaceutical Care Management Association (PCMA), claim that the rise in drug #costs is on the manufacturers, instead. Johnny Ray Garcia, senior director of policy at the PCMA, joined Drug Topics for an episode of #OverTheCounter to address common #misconceptions surrounding PBMs and what his organization is doing to help #patients. Want more #PBM content? From the perspective of #legal experts, independent #pharmacy owners, and leaders of #advocacy groups, be sure to catch up on our ongoing coverage of the industry’s #pharmaceutical middlemen: 🥼: 𝐇𝐨𝐰 𝐏𝐁𝐌𝐬 𝐈𝐦𝐩𝐚𝐜𝐭 𝐈𝐧𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬: https://lnkd.in/efbq4E9T 🥼: 𝐋𝐢𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧 𝐋𝐚𝐰𝐲𝐞𝐫 𝐨𝐧 𝐏𝐁𝐌𝐬 𝐚𝐧𝐝 𝐃𝐞𝐟𝐞𝐧𝐝𝐢𝐧𝐠 𝐈𝐧𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬: https://lnkd.in/e8fC67je 🥼: 𝐍𝐂𝐏𝐀 𝐑𝐞𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐯𝐞 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐞𝐬 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐜𝐢𝐧𝐠 𝐏𝐁𝐌 𝐑𝐞𝐟𝐨𝐫𝐦: https://lnkd.in/eS8yR-rh

The Foundation for Government Accountability (FGA) is suing the Department of Health and Human Services (HHS) for failing to provide transparent drug pricing information. The lawsuit seeks to compel the HHS to provide the information required by law, which includes negotiated prices between pharmacy benefit managers and drug manufacturers. The FGA believes that greater transparency in drug pricing will help lower costs for consumers and increase competition in the pharmaceutical industry. https://lnkd.in/gRud2ehT #tennesseehealthadvocates #medicalbills #patientadvocate #healthinsurance #reviewyourbills #understandyourbills #reviewyourmedicalbills #peaceofmind #billingerrors #savetime #savemoney #fairprice #strategy #information #medicalbillingprofessional

Empowering healthcare with affordable options! Discover how generic drug promotion and managed care are revolutionizing access to quality medications in #ManagedCareMondays #westernuamcp #managedcare #pharmacy #amcp #pharmacist #pharmacystudent #pharmd #pharmacystudents #pharmacists

Did you know? You can save up to six weeks by conducting your first-in-human trials in North America, compared to the EU! Starting Phase I clinical trials in the EU and the UK has become a more complex, resource-driven activity, considering the changes to the EU clinical trial application (CTA) preparation and submission process. Moreover, the Medicines and Healthcare Products and Regulatory Agency (MHRA) is transitioning to a more combined review process that is not fully implemented and therefore submission takes longer Discover more about how the regulatory processes in the EU, UK, U.S.A, and Canada compare in this eBook: https://lnkd.in/gjGMFY53 #DrugDevelopment #RegulatoryAffairs #Pharmaceuticals

💊 Medicine shortages in Europe have reached unprecedented levels as a result of the COVID-19 pandemic. Since the pandemic various protectionist measures have been implemented by the CEE & SEE region in the healthcare and pharmaceutical sector. ⚖️ We have leveraged our regional legal expertise in healthcare and life sciences to compile an all-encompassing guide addressing potential reasons behind the medicine shortages while detailing the planned legislative actions and procedures the jurisdictions are adopting to address them. This new guide will prove particularly helpful for companies seeking to use internal policies, rules and distribution strategies to manage the supply of certain medicines nationally. Download the guide now via 🔗 https://wt.legal/Llh_ #WolfTheiss #MedicineShortages #Healthcare #HealthcareIndustry #Pharmaceuticals #MedicineSupply

Stand Up Against Big Pharma's Greed: Join Our Digital Day of Action! 📅 Date: June 27th 💻 Where: P4AD Facebook Live 📢 Event: Panel Discussion on Defending Medicare Negotiation and Big Pharma's Lawsuits to Block the Critical Program 🔗 RSVP: https://lnkd.in/e7mYPPrP Big Pharma has filed 9 lawsuits to block Medicare from negotiating lower drug prices. Their greed has forced many patients to ration their medications or skip treatments because of the outrageous costs of their medications. Join us on June 27th for a virtual panel discussion where experts will highlight the critical need for Medicare negotiation. We aim to gather 250,000 signatures demanding that pharmaceutical CEOs #DropTheSuits and prioritize patients over profits. #FightPharma

𝗗𝗶𝘃𝗲𝗿𝗴𝗲𝗻𝘁 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 ⚖️𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗠𝗮𝗸𝗶𝗻𝗴 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗦𝗮𝗳𝗲𝘁𝘆 ✅Have you noticed how the FDA and EMA often simultaneously release their drug safety decisions? What drives these actions? While both aim to ensure public safety and treatment access, their choices can differ due to unique regulatory approaches. Our latest blog post explores these differences. Understanding these distinctions is crucial for professionals navigating the global #pharmaceutical landscape, ensuring compliance, and enhancing patient safety. 🔍 Key Takeaways: 1️⃣Comparative analysis of #FDA and #EMA regulatory processes. 2️⃣Case studies illustrating real-world implications. 3️⃣Regulatory Decision-Making Factors. 🔥Stay ahead in your field and join the discussion on how these regulatory differences influence global drug safety. Your insights and experiences are valuable to us! 🔗 Dive into the details: https://lnkd.in/dmuqiVCc